Document is current
Any future updates will be listed below
-
Authors
Vringer, Esmee https://orcid.org/0000-0003-2083-8567
Heilig, Rosalie https://orcid.org/0000-0002-8813-9933
Riley, Joel S https://orcid.org/0000-0001-9170-5716
Black, Annabel https://orcid.org/0009-0001-1082-8034
Cloix, Catherine
Skalka, George
Montes-Gómez, Alfredo E https://orcid.org/0000-0002-8487-7592
Aguado, Aurore https://orcid.org/0009-0000-1237-127X
Lilla, Sergio https://orcid.org/0000-0003-3142-7640
Walczak, Henning https://orcid.org/0000-0002-6312-4591
Gyrd-Hansen, Mads https://orcid.org/0000-0001-5641-5019
Murphy, Daniel J https://orcid.org/0000-0002-5538-5468
Huang, Danny T https://orcid.org/0000-0002-6192-259X
Zanivan, Sara
Tait, Stephen WG https://orcid.org/0000-0001-7697-132X
-
Funding
Funding for this research was provided by:
Cancer Research UK (A20145)
Cancer Research UK (A29256)
Cancer Research UK (A29800)
Cancer Research UK (DRCNPG-Jun22\100011)
Cancer Research UK (DRCNPG-Jun22\100007)
Cancer Research UK (EDDPGM-Nov21\100001)
Cancer Research UK (A31287)
Cancer Research UK (A18076)
Cancer Research UK (A17196)
Cancer Research UK (A27323)
Wellcome Trust (214342/Z/18/Z)
Novo Nordisk (NNF20OC0059392)
Deutsche Forschungsgemeinschaft (SFB1399)
Deutsche Forschungsgemeinschaft (SFB1530-455784452)
Deutsche Forschungsgemeinschaft (SFB1403-414786233)
UKRI | Medical Research Council (MR/S00811X/1)
- License Information
-
More Information
Article History
Received: 20 February 2023
Revised: 15 January 2024
Accepted: 16 January 2024
First Online: 9 February 2024
Disclosure and competing interests statement
: SWGT consults for Exo Therapeutics. DTH consults for Triana Biomedicines. Salary support for GS was provided by a collaborative agreement with the Merck Group and Cancer Research Horizons UK. DJM has additionally received support from Puma Biotechnology and ORIC Pharmaceuticals. The remaining authors declare no competing interests.
